|Description||4SC-203 is a multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated.|
|Synonyms||SC71710; SC-71710; SC 71710.|
|Current Developer||4SC AG|
p-MPPI is a selective 5-HT1A antagonist.
Balofloxacin is a quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enqyme DNA gyrase.
Famitinib is a novel multi-targeted receptor tyrosine kinase inhibitor under development for cancer treatment. Famitinib is a structural analogue ofsunitinib, ...
Mutant EGFR inhibitor
Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted from patent WO 2013014448 A1. It inhibits EGFRL858R, EGFRExon 19 deletionand EGF...
EC330 is a novel steroidal LIF inhibitor showed cytotoxicity in various cancer cell lines and NCI-60 cell line panel at low nano-molar range, blocked formation ...
Gonadorelin, a synthetic decapeptide prepared using solid phase peptide synthesis, is another name for gonadotropin-releasing hormone (GnRH) for evaluating th...
TMP269 is a highly potent, selective and cell-permeable class IIa HDAC inhibitor with IC50 values of 126 nM, 80 nM, 36 nM and 19 nM for HDAC4, HDAC5, HDAC7 and ...
MEN 10376 is a selective NK2 receptor antagonist.